synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Tryptophan N-monooxygenase is a cytochrome P450 protein containing heme, first isolated from Sinapis alba. It uses molecular oxygen for the oxidation and requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate. The reaction proceeds via N-hydroxylation to an intermediate which loses carbon dioxide. The product of the reaction is an intermediate in the biosyntheis of the auxin, indole acetic acid, and the phytoalexin, camalexin.
The early or fulminant form of hemorrhagic smallpox (referred to as purpura variolosa) begins with a prodromal phase characterized by a high fever, severe headache, and abdominal pain. The skin becomes dusky and erythematous, and this is rapidly followed by the development of petechiae and bleeding in the skin, conjunctiva and mucous membranes. Death often occurs suddenly between the fifth and seventh days of illness, when only a few insignificant skin lesions are present. Some people survive a few days longer, during which time the skin detaches and fluid accumulates under it, rupturing at the slightest injury. People are usually conscious until death or shortly before. Autopsy reveals petechiae and bleeding in the spleen, kidney, serous membranes, skeletal muscles, pericardium, liver, gonads and bladder. Historically, this condition was frequently misdiagnosed, with the correct diagnosis made only at autopsy. This form is more likely to occur in pregnant women than in the general population (approximately 16% of cases in unvaccinated pregnant women were early hemorrhagic smallpox, versus roughly 1% in nonpregnant women and adult males). The case fatality rate of early hemorrhagic smallpox approaches 100%.
It has the potential of enhancing protein tyrosine phosphorylation, which takes place during capacitation, and its effects are inhibited in the presence of lidocaine and tetrodotoxin. Veratridine has not been reported to have any effect on the acrosome reaction on its own, but it is able to block the progesterone-induced acrosome reaction. Moreover, veratridine has the effect of turning the membrane potential to a more positive one and also modifies the effect of progesterone on [Ca2+]i and sperm membrane potential. The activation of Nav1.8 is a key point in Veratradine's mechanism of action and, consequently, this sodium ion channel coordinates the effects of this compound. Veratradine also activates additional NaV channels. These facts contribute to support the importance of these Veratradine-sensitive proteins in the regulation of mature sperm function, such as human sperm fertility acquisition regulating motility, capacitation and the progesterone-induced acrosome reaction. Veratridine has been synthetically modified to introduce a photoswitchable azobenzene group (azoveratridine) that allows controlling the NaV potentiating activity with light in neurons and cardiac cells. Using this method, further late-stage modifications are possible, including the introduction of fluorescent and radioactive tags.
Sources: en.wikipedia.org
== Differences between countries == The sirloin steak is called the rump steak in British butchery. In common British, South African, and Australian butchery, sirloin refers to cuts of meat from the upper middle of the animal, similar to the American short loin, while the American sirloin is called the rump. These differences arise from butchery traditions and standard cutting systems, but can lead to confusion. For example, the T-bone steak is classified as part of the sirloin in British butchery, but as part of the short loin in American butchery.
Canada-wide in 2014, they were technically illegal to sell, as no nicotine-containing e-cigarettes are not regulated by Health Canada, but this is generally unenforced and they are commonly available for sale Canada-wide. In 2016, Health Canada announced plans to regulate vaping products. In the US and the UK, the use and sale to adults of e-cigarettes are legal. The revised EU Tobacco Products Directive came into effect in May 2016, providing stricter regulations for e-cigarettes. It limits e-cigarette advertising in print, on television and radio, along with reducing the level of nicotine in liquids and reducing the flavors used. It does not ban vaping in public places. It requires the purchaser for e-cigarettes to be at least 18 and does not permit buying them for anyone less than 18 years of age. The updated Tobacco Products Directive has been disputed by tobacco lobbyists whose businesses could be impacted by these revisions. The US FDA regulates e-cigarettes, e-liquid and all related products. It evaluates ingredients, product features and health risks, as well their appeal to minors and non-users. The FDA rule also bans access to minors. A photo ID is now required to buy e-cigarettes, and their sale in all-ages vending machines is not permitted in the US.
=== Nanoparticle drug delivery === Delivering medications to the brain has long been a significant challenge in treating neurological diseases. The main reason lies in the blood-brain barrier (BBB), a highly selective, protective layer that shields the brain from toxins and pathogens in the bloodstream. While the BBB is crucial for maintaining brain health, it also makes it difficult for most therapeutic drugs to reach their target, especially in conditions like Alzheimer's and Parkinson's disease. As a result, conventional drug delivery methods often fall short, either causing unwanted side effects or failing to deliver a high enough concentration to be effective. To address this, researchers have turned to nanoparticles, tiny engineered carriers designed to sneak past the BBB and deliver drugs directly to the brain tissue These particles can be tailored to take advantage of the body's own transport systems. For example, by attaching certain molecules to their surfaces, nanoparticles can trigger receptor-mediated transcytosis, a natural process that allows them to pass through cells lining the BBB and enter the brain. This kind of targeted delivery helps reduce the drug's exposure to the rest of the body, lowering the risk of side effects and increasing concentration where it matters most. So far, this strategy has shown promise in delivering treatments to the brain for conditions like Alzheimer's and Parkinson's disease. Several types of nanoparticles are being studied for this purpose.
Sources: en.wikipedia.org
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina, US-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with BHV. In 2002, GlaxoSmithKline (GSK) received a license to use it. From 2002 to 2009, GSK carried out a significant clinical development program for the treatment of type-2 diabetes mellitus in various nations across the world and obesity in the UK. Remogliflozin etabonate's pharmacokinetics, pharmacodynamics, and clinical dose regimens were characterized in 18 Phase I and 2 Phase II investigations. Due to financial concerns, GSK stopped working on remogliflozin and sergliflozin, two further SGLT2 inhibitors that were licensed to the company, in 2009. Remogliflozin was commercially launched first in India by Glenmark in May 2019.
=== Issues of dosage quantification and standardization === As Knopp and her associates note (JK.1), a manufacturer's standard sample has its universally agreed-upon potency (i.e., its specific biological activity) precisely expressed, by convention, in international units (IU), with one international unit of insulin (1 IU) defined as the "biological equivalent" of 34.7 μg pure crystalline insulin. Yet, as they also note, there is no universally agreed-upon "conversion factor" to express the mass of that same sample in International System Units (SI).
Gram Parsons died from a drug and alcohol overdose on September 19, 1973. He was 26 years old. In the late 1960s, Parsons began to vacation at Joshua Tree National Monument in southeastern California, where he used psychedelics and said he experienced UFO sightings. After splitting from Burrell, Parsons often spent his weekends there with Margaret Fisher and Phil Kaufman. Scheduled to resume touring in October 1973, Parsons decided to go on another recuperative excursion on September 17. Accompanying him were Fisher, his assistant Michael Martin, and Martin's girlfriend Dale McElroy. On both nights of their stay, Parsons retreated to the desert, consuming large amounts of alcohol and barbiturates, while the rest of the group visited bars in nearby Yucca Valley. On September 18, Martin drove back to Los Angeles to resupply the group with marijuana. That night, Parsons challenged Fisher and McElroy to drink with him; Fisher did not drink and McElroy was recovering from illness. Parsons said that he would drink for the three of them and drank six double tequilas. The three then went to the Joshua Tree Inn, where Parsons purchased morphine from an unknown woman; after being injected by her in Room No. 1, he overdosed. Fisher gave Parsons an ice cube suppository, and then a cold shower and moved him to Room No. 8. She put him to bed and went out to buy coffee in the hope of reviving him, leaving McElroy to stand guard. As his breathing became irregular and then ceased, McElroy attempted resuscitation. After all attempts failed, they called an ambulance.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.